Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 3, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 3, 2023Terminated
Condition(s):Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and CholangiocarcinomaLast Updated:December 19, 2023Completed
Condition(s):CholangiocarcinomaLast Updated:November 18, 2023Active, not recruiting
Condition(s):Solid TumorLast Updated:June 5, 2023Completed
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:July 3, 2023Terminated
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene RearrangementLast Updated:March 8, 2024Recruiting
Condition(s):Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene TranslocationLast Updated:August 28, 2023Recruiting
Condition(s):Malignant Hepatobiliary NeoplasmLast Updated:November 25, 2020Completed
Condition(s):FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Other Solid Tumors, AdultLast Updated:March 5, 2024Active, not recruiting
Condition(s):Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor; Metastatic CholangiocarcinomaLast Updated:March 7, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.